ArticleRespiratory research2020
Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment - a German claims data analysis.
Article in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Association of CYFRA 21-1 with quantitative CT-defined fibrotic progression in idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2026Article
- Retrospective analysis of acute admissions for interstitial lung disease suggests a complex, multifactorial association between social deprivation and 90-day all-cause mortality: data from the North West of England.BMJ open respiratory research · 2026Article
- Mortality and diagnostic practice variation in interstitial lung disease admissions: insights from a multicentre UK cohort study.BMJ open respiratory research · 2026Article
- Correlation between CT-based phenotypes and serum biomarker in interstitial lung diseases.BMC pulmonary medicine · 2024Observational
- Hospitalizations as Clinical Trials Endpoint in Interstitial Lung Disease: Are We There Yet?American journal of respiratory and critical care medicine · 2024Article
- Risk Factors for Hospital Readmission in Patients With Interstitial Lung Disease.Respiratory care · 2024Article
- Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry.Respiratory research · 2024Article
- Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry.Respiratory research · 2024Article
- Re-hospitalisation predicts poor prognosis after acute exacerbation of interstitial lung disease.BMC pulmonary medicine · 2023Article
- Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study.BMC pulmonary medicine · 2023Article
- Review
- Comparing outcomes of ILD patients managed in specialised versus non-specialised centres.Respiratory research · 2022Article
- Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis.Respiratory research · 2022Article
- Sex and gender in interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2021Article
- Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.Respiratory research · 2021Article
- Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases.PloS one · 2020Article
- Clinical impact of hospitalization in patients with idiopathic pulmonary fibrosis: A retrospective cohort study.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial lung disease (ILD) is a heterogeneous group of mainly chronic lung diseases differing in disease course and prognosis. For most subtypes, evidence on relevance and outcomes of hospitalisations is lacking.
methodsUsing German claims data we investigated number of hospitalisations (zero-inflated-negative-binomial models providing rate ratios (RR)) and time to first hospitalisation (Cox proportional-hazard models providing hazard ratios (RR)) for nine ILD-subtypes. Models were stratified by ILD-related and non-ILD-related hospitalisations. We adjusted for age, gender, ILD-subtype, ILD-relevant comorbidities and ILD-medication (immunosuppressive drugs, steroids, anti-fibrotic drugs).
resultsAmong 36,816 ILD-patients (mean age 64.7 years, 56.2% male, mean observation period 9.3 quarters), 71.2% had non-ILD-related and 56.6% ILD-related hospitalisations. We observed more and earlier non-ILD-related hospitalisations in ILD patients other than sarcoidosis. Medical ILD-treatment was associated with increased frequency and in case of late initiation, earlier (non-)ILD-related hospitalisations. Comorbidities were associated with generally increased hospitalisation frequency except for COPD (RR = 0.90) and PH (RR = 0.94) in non-ILD-related and for lung cancer in ILD-related hospitalisations (RR = 0.89). Coronary heart disease was linked with earlier (ILD-related: HR = 1.17, non-ILD-related HR = 1.19), but most other conditions with delayed hospitalisations.
conclusionHospitalisations are frequent across all ILD-subtypes. The hospitalisation risk might be reduced independently of the subtype by improved management of comorbidities and improved pharmacological and non-pharmacological ILD therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.